American journal of kidney diseases : the official journal of the National Kidney Foundation

Use, Costs, Evidence, and Rules for Phosphate Binders in US Dialysis Patients

Updated

Abstract

Medicare costs for phosphate binders for US dialysis patients exceeded $1.5 billion in 2015.

  • Costs for mineral and bone disorder medications in dialysis patients have increased faster than overall Part D medication costs.
  • Extensive use of phosphate binders has occurred despite insufficient evidence showing their effectiveness in improving clinical outcomes.
  • Updated trends in phosphate-binder use, calcium and phosphorus values, and costs were analyzed using data from the US Renal Data System and CMS.
  • A need for US Food and Drug Administration guidance on the clinical evaluation of new phosphate binders is indicated.
  • Funding for a clinical trial to explore the impact of phosphate concentrations on clinical outcomes is suggested.

Simplified

Full Text

Full text is available at the source.

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free